Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04205994 · ClinicalTrials.gov registry record · Early Phase 1

Dopaminergic Mechanisms Underlying Human Social Behavior

A Early Phase 1 study, sponsored by University of California, Berkeley.

Completed
Registry status
Early Phase 1
Development phase
70
Enrollment target

NCT04205994 is a Early Phase 1 study that has completed, run by University of California, Berkeley. The registered enrollment target is 70 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04205994, a Early Phase 1 study, has completed, sponsored by University of California, Berkeley.

COMPLETED
Registry status
Early Phase 1
Development phase
70 participants
Enrollment target

Study Summary

Developing theoretical, quantitative models of the basic cognitive mechanisms underlying human social decision-making, and understanding the influence of neuromodulators such as dopamine on these mechanisms, has important ramifications for both healthy and patient populations. In this proposal the investigators combine quantitative social measures, computational models, neuroimaging, and a pharmacological intervention to define the mechanisms of social decision-making.

Interventions

  • OTHER Functional Magnetic Resonance Imaging (fMRI)
  • DRUG Tolcapone 200 MG

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2019-12-01
Est. Completion 2023-12-31
Phase Early Phase 1

Sponsor

University of California, Berkeley

72 total trials

What the Registry Record Tells You About NCT04205994

The ClinicalTrials.gov registry entry for NCT04205994 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Berkeley, which has 72 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Functional Magnetic Resonance Imaging (fMRI) is the first listed.

NCT04205994 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04205994 about?

NCT04205994 is a clinical study titled "Dopaminergic Mechanisms Underlying Human Social Behavior". Developing theoretical, quantitative models of the basic cognitive mechanisms underlying human social decision-making, and understanding the influence of neuromodulators such as dopamine on these mechanisms, has important ramifications for both healthy and patient populations. In this proposal the i...

What is the current status of trial NCT04205994?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 70 participants. The study started on 2019-12-01. Estimated completion is 2023-12-31.

What interventions are being tested in trial NCT04205994?

The interventions under investigation include: Functional Magnetic Resonance Imaging (fMRI) (OTHER), Tolcapone 200 MG (DRUG).

Who is sponsoring clinical trial NCT04205994?

This trial is sponsored by University of California, Berkeley, which has 72 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.